Resources Year All 2019 2018 2017 2016 2015 2014 2013 2012 2010 Go Search Paper Targeting Cancer at the Nuclear Pore External Link Read MorePaper Clinical dosing regimen of selinexor maintains normal immune homeostasis and T cell effector function in mice: implications for combination with immunotherapy External Link Read MorePaper Selective Inhibitor of Nuclear Export (SINE) Compounds Alter New World Alphavirus Capsid Localization and Reduce Viral Replication in Mammalian Cells PDF (2.43 MB) Read MorePaper Nuclear export of ubiquitinated proteins determines the sensitivity of colorectal cancer to proteasome inhibitor External Link Read MorePaper Antiviral Efficacy of Verdinexor In Vivo in Two Animal Models of Influenza A Virus Infection PDF (1.65 MB) Read MorePaper Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma PDF (4.91 MB) Read MorePaper Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting External Link Read MorePaper XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma PDF (5.34 MB) Read MorePaper The second-generation exportin-1 inhibitor KPT-8602 demonstrates potent activity against acute lymphoblastic leukemia PDF (3.69 MB) Read MorePresentation RAS/AKT pathway mutations as predictive biomarkers in patients with colorectal cancer treated with the exportin 1 (XPO1) inhibitor selinexor (SEL) – inhibition of nuclear-cytoplasmic translocation of p27 as a mechanism of anti-tumour activity PDF (1.44 MB) Read More Previous 1 … 5 6 7 8 9 … 22 Next